If you’re searching for a retatrutide pen for sale, you’re likely aware of the remarkable clinical trial results showing weight loss of up to 24.2% of total body weight. This triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors has generated enormous interest worldwide, and Australian researchers are among those seeking access.